1 recruiting, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Trastuzumab plus Pertuzumab: new trials by email Literature Review of Trastuzumab plus Pertuzumab trials Research Report on Trastuzumab plus Pertuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) Olaparib, Dasatinib, Nivolumab plus Ipilimumab - Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 720 | 2018-03-23 | 2026-03-27 |
| 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin - Metastatic Breast Cancer | Phase 2 | Terminated | University of Maryland, Baltimore | 2 | 2014-01-01 | 2022-05-27 |
Breast Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1)
Canadian Cancer Trials Group (1) · University of Maryland, Baltimore (1)
Canada (1) · United States (1)
Daniel J Renouf (1) · Katherine Tkaczuk, MD (1) · Lillian Siu (1)